Latest Erlotinib Stories

AUSTIN, Texas, Oct. 20, 2011 /PRNewswire/ -- Genprex, Inc. announced today that it will be presenting at the upcoming BIO Investor Forum, to be held in San Francisco. Greg Heinlein, Chief Operating and Financial Officer, is scheduled to present at the 10th annual BIO Investor Forum, on October 25 starting at 11 a.m. PDT in The Palace Hotel. A copy of the presentation slides will be made available on the company's website under the News & Media section on the day of the presentation....

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex(TM), was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation...

BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. Patients who tested VeriStrat Good had significantly longer progression free survival (PFS) and overall survival...

PORTSMOUTH, N.H., Oct. 5, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that Gabriel Leung has joined its board of directors. Mr. Leung will serve as vice chairman of the board of directors and chairman of the company's global commercialization team. Mr. Leung retired as executive vice president of OSI Pharmaceuticals and the President of OSI's Pharmaceuticals Business following the Astellas Pharma Inc. acquisition of OSI in 2010. Mr. Leung...

AUSTIN, Texas, Sept. 6, 2011 /PRNewswire/ -- Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex(TM). "We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs. We anticipate that when approved, Oncoprex will be used to unlock the unrealized potential of a growing list of cancer therapies that have...

WALTHAM, Mass., Aug. 24, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that safety and efficacy data from ENCORE 301 will be presented in an oral session at the ASCO Breast Cancer Symposium 2011 on Saturday, September 10 in San Francisco, CA. "Endocrine therapy, such as aromatase inhibitors, is the backbone of treatment of estrogen receptor positive (ER+) breast cancer but unfortunately resistance in women with advanced...

WALTHAM, Mass., Aug. 17, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B." This allowance follows the recent US issuance which was granted in June adding to the extensive patent estate for the Company's lead product, entinostat. The patent covers the novel...

SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer. Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610. The initial agreement, signed in February 2011, for...

AUSTIN, Texas, July 14, 2011 /PRNewswire/ -- Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy...

Award to Recognize Luminaries in the Quest to Eradicate Lung CancerSAN FRANCISCO, July 6, 2011 /PRNewswire-USNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (BJALCF) today announced the winner of the 2011 Addario Lectureship Award, which each year recognizes luminaries in the quest to eradicate Lung Cancer. The recipient will be honored at the 12th International Lung Cancer Congress in Carlsbad, California to be held on August 11-14, 2011.(Photo:...